Published in Genetics and Environmental Health Week, September 20th, 2006
According to a study from Austria, "We investigated the roles of nitric oxide (NO) and endothelin-1 (ET-1) in organ dysfunction in diabetic mice with normal genotype (wild-type, WT) or myocyte-specific overexpression of endothelial NO synthase (eNOS) (transgenic, TG) after chronic oral treatment with the endothelin-A(ET A) receptor antagonist atrasentan."
"Mice were rendered diabetic by injection of 200 mg/kg streptozotocin (STZ)....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.